Literature DB >> 15919938

Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.

Koert J Stittelaar1, Geert van Amerongen, Ivanela Kondova, Thijs Kuiken, Rob F van Lavieren, Frank H M Pistoor, Hubert G M Niesters, Gerard van Doornum, Ben A M van der Zeijst, Luis Mateo, Paul J Chaplin, Albert D M E Osterhaus.   

Abstract

The use of classical smallpox vaccines based on vaccinia virus (VV) is associated with severe complications in both naive and immune individuals. Modified vaccinia virus Ankara (MVA), a highly attenuated replication-deficient strain of VV, has been proven to be safe in humans and immunocompromised animals, and its efficacy against smallpox is currently being addressed. Here we directly compare the efficacies of MVA alone and in combination with classical VV-based vaccines in a cynomolgus macaque monkeypox model. The MVA-based smallpox vaccine protected macaques against a lethal respiratory challenge with monkeypox virus and is therefore an important candidate for the protection of humans against smallpox.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15919938      PMCID： PMC1143678          DOI： 10.1128/JVI.79.12.7845-7851.2005

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  24 in total

1.  Detection of smallpox virus DNA by LightCycler PCR.

Authors:  Mark J Espy; Franklin R Cockerill III; Richard F Meyer; Michael D Bowen; Gregory A Poland; Ted L Hadfield; Thomas F Smith
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

Review 2.  Clinical virology in real time.

Authors:  Hubert G M Niesters
Journal:  J Clin Virol       Date:  2002-12       Impact factor: 3.168

3.  Development of vaccines for bio-warfare agents.

Authors:  S R Rosenthal; J C M Clifford
Journal:  Dev Biol (Basel)       Date:  2002

Review 4.  Progressive vaccinia.

Authors:  Mike Bray; Mary E Wright
Journal:  Clin Infect Dis       Date:  2003-02-20       Impact factor: 9.079

5.  The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis).

Authors:  G M Zaucha; P B Jahrling; T W Geisbert; J R Swearengen; L Hensley
Journal:  Lab Invest       Date:  2001-12       Impact factor: 5.662

Review 6.  Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Authors:  D A Henderson; T V Inglesby; J G Bartlett; M S Ascher; E Eitzen; P B Jahrling; J Hauer; M Layton; J McDade; M T Osterholm; T O'Toole; G Parker; T Perl; P K Russell; K Tonat
Journal:  JAMA       Date:  1999-06-09       Impact factor: 56.272

7.  Expected adverse events in a mass smallpox vaccination campaign.

Authors:  Alex R Kemper; Matthew M Davis; Gary L Freed
Journal:  Eff Clin Pract       Date:  2002 Mar-Apr

8.  Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

Authors:  K J Stittelaar; L S Wyatt; R L de Swart; H W Vos; J Groen; G van Amerongen; R S van Binnendijk; S Rozenblatt; B Moss; A D Osterhaus
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

9.  Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001.

Authors:  Hermann Meyer; Mathilde Perrichot; Markus Stemmler; Petra Emmerich; Herbert Schmitz; Francis Varaine; Robert Shungu; Florimond Tshioko; Pierre Formenty
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

Review 10.  Smallpox vaccination and bioterrorism with pox viruses.

Authors:  Anton Mayr
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2003-10       Impact factor: 2.268
View more
  84 in total

1.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

2.  Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys.

Authors:  Rafal J Zielinski; Jeremy V Smedley; Pin-Yu Perera; Peter M Silvera; Thomas A Waldmann; Jacek Capala; Liyanage P Perera
Journal:  Vaccine       Date:  2010-08-20       Impact factor: 3.641

3.  Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Authors:  Janie Parrino; Lewis H McCurdy; Brenda D Larkin; Ingelise J Gordon; Steven E Rucker; Mary E Enama; Richard A Koup; Mario Roederer; Robert T Bailer; Zoe Moodie; Lin Gu; Lihan Yan; Barney S Graham
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

4.  Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection.

Authors:  Ryan D Estep; Ilhem Messaoudi; Megan A O'Connor; Helen Li; Jerald Sprague; Alexander Barron; Flora Engelmann; Bonnie Yen; Michael F Powers; John M Jones; Bridget A Robinson; Beata U Orzechowska; Minsha Manoharan; Alfred Legasse; Shannon Planer; Jennifer Wilk; Michael K Axthelm; Scott W Wong
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 5.  Migration, maintenance and recall of memory T cells in peripheral tissues.

Authors:  David L Woodland; Jacob E Kohlmeier
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

6.  Evaluation of monkeypox disease progression by molecular imaging.

Authors:  Julie Dyall; Reed F Johnson; Dar-Yeong Chen; Louis Huzella; Dan R Ragland; Daniel J Mollura; Russell Byrum; Richard C Reba; Gerald Jennings; Peter B Jahrling; Joseph E Blaney; Jason Paragas
Journal:  J Infect Dis       Date:  2011-10-19       Impact factor: 5.226

7.  Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.

Authors:  Graham J Hatch; Victoria A Graham; Kevin R Bewley; Julia A Tree; Mike Dennis; Irene Taylor; Simon G P Funnell; Simon R Bate; Kimberley Steeds; Thomas Tipton; Thomas Bean; Laura Hudson; Deborah J Atkinson; Gemma McLuckie; Melanie Charlwood; Allen D G Roberts; Julia Vipond
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

8.  Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Authors:  Richard N Greenberg; Edgar Turner Overton; David W Haas; Ian Frank; Mitchell Goldman; Alfred von Krempelhuber; Garth Virgin; Nicole Bädeker; Jens Vollmar; Paul Chaplin
Journal:  J Infect Dis       Date:  2012-12-07       Impact factor: 5.226

9.  Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Authors:  Jay W Hooper; Anthony M Ferro; Joseph W Golden; Peter Silvera; Jeanne Dudek; Kim Alterson; Max Custer; Bryan Rivers; John Morris; Gary Owens; Jonathan F Smith; Kurt I Kamrud
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

10.  Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.

Authors:  Patricia L Earl; Jeffrey L Americo; Linda S Wyatt; Ondraya Espenshade; Jocelyn Bassler; Kathy Gong; Shuling Lin; Elizabeth Peters; Lowrey Rhodes; Yvette Edghill Spano; Peter M Silvera; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-04       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.